A pharmaceutical firm’s OTC business unit was stagnating in the US and underperforming internationally, so they turned to Marakon. We designed granular resource allocation strategies to unlock profitable growth in US while turning around Mexico and China businesses. These changes drove double digit top line and >2x EBIT in target regions and ultimately resulted in the sale of the business unit at 100% premium to intrinsic value.
Exclusive dealings in multisided platform markets: The case of Gympass in Brazil
Introduction. In 2020, the wellness platform Totalpass filed a complaint before the Brazilian antitrust authority (CADE) claiming that a competitor, Gympass,...